Borrelia mayonii sp. nov., a member of the Borrelia burgdorferi sensu lato complex, detected in patients and ticks in the upper midwestern United States
AbstractDecision aids are evidenced‐based tools designed to increase patient understanding of medical options and possible outcomes, facilitate conversation between patients and clinicians, and improve patient engagement. Decision aids have been used for shared decision making (SDM) interventions outside of the ED setting for more than a decade. Their use in the ED has only recently begun to be studied. This article provides background on this topic and the conclusions of the 2016 Academic Emergency Medicine consensus conference SDM in practice work group regarding “Shared Decision Making in the Emergency Department: Development of a Policy‐Relevant, Patient‐Centered Research Agenda.” The goal was to determine a prioritized research agenda for the development and testing of SDM interventions for use in emergency care that was most important to patients, clinicians, caregivers, and other key stakeholders. Using the nominal group technique, the consensus working group proposed prioritized research questions in six key domains: 1) content (i.e., clinical scenario or decision area), 2) level of evidence available, 3) tool design strategies, 4) risk communication, 5) stakeholders, and 6) outcomes.
Abstract PD2-03: Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)
Abstract Background: AI's are more effective than TAM in ER+ breast cancer. In AI refractory MBC, the response rate to TAM is 0% (Osborne 2011). Z-Endx is an active metabolite of TAM and among TAM treated women in the adjuvant and metastatic settings, reduced CYP2D6 metabolism and low Endx concentrations (Css <20 nM) have been associated with increased likelihood of disease recurrence. Preclinical studies have demonstrated greater Z-Endx exposure and anti-tumor activity with oral Z-Endx compared to equivalent doses of oral TAM (Reid 2014) Methods: We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and evaluate the toxicities, clinical activity, and pharmacokinetics (PK) of Z-Endx in patients (pts) with ER+, AI refractory MBC. Unlimited prior endocrine regimens were allowed. An accelerated titration schedule was applied (2 pts/dose level) until moderate toxicity or DLT, followed by a 3+3 design and then to expansion cohorts (40, 80, and 100 mg/day). Z-Endx was administered orally once daily (28 day cycle). Eye exams were performed at baseline, and end of cycles 2 and 6. PK was performed during cycle 1 and prior to subsequent cycles. For pts in the expansion cohorts, tumor biopsies were obtained at baseline for DNA sequencing (Foundation Medicine). Plasma cholesterol levels were obtained at baseline and after 1 cycle. Results: From March 2011 to Dec 2014, 41 pts (38 evaluable), median age 60, received Z-Endx once daily encompassing 7 dose levels (20-160 mg/daily). The median number of prior hormonal regimens was 2 and 3 for the dose escalation and expansion cohorts, respectively. Dose escalation was stopped at 160 mg/day given MTD not reached and attainment of mean Endx Css of 3.6 uM. Cycle 1 DLT (PE) was observed in one patient (60 mg). No eye toxicity was observed. PK demonstrated mean Endx Css of > 1 uM at all dose levels ≥ 40 mg/day. Antitumor activity was observed at multiple dose levels including 3 confirmed partial responses and an additional 7 with stable disease for ≥6 cycles. Of these 10 pts, 9 had prior progression on both AI and fulvestrant and 3 additionally on TAM. After 1 cycle, total and LDL cholesterol decreased > 20 points in 54% and 40% of pts, respectively. Tumor sequencing in the expansion cohorts (n=14) did not identify ESR1 mutations; however, ESR1 amplification was identified in 1 pt with prolonged stable disease (>200 days). Of 6 pts with rapid progression (≤2 cycles), 4/6 had either CCND1 amplification (n=1) or at least one of the following activating mutations: ERBB2 L755S (n=1), AKT1 E17K (n=1), MTOR E1799K (n=1). Conclusions: The direct administration of Z-END provides substantial drug exposure, acceptable toxicity, and "proof of principle" antitumor activity in endocrine resistant MBC. While the MTD was not determined, the goal of achieving Endx Css concentrations of > 1 uM was achieved. Tumor sequencing identified pts with predicted and confirmed endocrine resistance. A randomized phase II comparing endoxifen (80 mg/day) with TAM in AI refractory MBC was recently activated (NCT02311933). Supported in part by CA 133049, CA186686, CA15083, CA116201, and CA15083. Citation Format: Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Dockter T, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Collins JM, Streicher H, Hawse JR, Haddad TC, Erlichman C, Ames MM, Ingle JN. Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD2-03.
Abstract P5-05-06: Cobalamin metabolism in breast cancer
Abstract Cobalamin (Cbl) has two canonical co-enzymatic functions within mammalian cells. In the cytoplasm methylcobalamin promotes the synthesis of methionine, thymidine, and S-adenosylmethionine to sustain the anabolism of proteins, DNA, and multiple methylation reactions, respectively. Within the mitochondria, 5-deoxyadenosylcobalamin (AC) facilitates the final step in the catabolism of branched chain amino acids, odd chain fatty acids and cholesterol for ATP production. Methods and Findings: To assess Cbl metabolism within breast tumors, Cbl plasma levels where obtained in 20 women with suspicious breast lesions. Next 0.25 ug of an Indium-111 (In-111) radiolabeled AC analog was intravenously administered and quantitatively imaged at 2-5 hours after injection with single photon emission computed tomography. Within the cohort, 17 were found to have tumors at biopsy, while 3 had benign pathology. Of the 17 breast cancers, 94.1% (16/17) had increased In-111 AC metabolism. Most of the In-111 AC avid breast cancers were in foci of invasive, high nuclear grade ductal carcinoma and were imaged independent of their estrogen (ER), progesterone (PR), or Herceptin (HER2) receptor status. Foci of high grade ductal carcinoma in situ (DCIS), and single cases of invasive lobular, inflammatory and triple negative (TN) tumors were also depicted. Excluding one patient with a large, 7.5cm breast tumor, the average tumor size was 1.9 cm (range 0.7 - 3.4 cm). The average T:B ratio of the 16 true positive (TP) In-111 AC avid breast cancers was 5.8 (range 2.0-22.5). Four TP patients had ingested Cbl or dexamethasone (DEX) 24 hrs prior to their scans. The average T:B ratios in their tumors was 12.8 (range 5.9- 22.5) with an average Cbl plasma concentration of 1,150 (range 710-2000 ng/L). In the 12 TP patients that had not ingested Cbl or DEX 24 hrs prior to tracer injection, the T:B ratio was 3.5 (2.0-5.6) with an average Cbl plasma concentration of 400 (range 70-580 ng/L). The 3 true negative (TN) scans had an average T:B ratio of 1.2 (range 1.0-1.5). The one false negative (FN) scan was a low grade well differentiated tubular carcinoma with a T:B ratio of 1.8. In these four patients the average Cbl plasma concentration was 402 (range 350-488 ng/L). Pulse-chase (PC) studies in 8-12 weeks old, 20-25g nude mice burdened with the MDA-MB-231 TN breast tumors demonstrated that the administration of 2.0 ug of non-labeled AC at 2, 8, or 24 hrs prior to the injection of 0.5 ug of In-111 AC increased the In-111 AC uptake within the TN tumors by an average of 21.5%, 67.6%, and 90.6%, respectively. This occurred despite the doses of AC and In-111 AC being 20 and 5 times the respective maximum murine recommended daily allowance for Cbl. The DEX 24 hr PC interval increased In-111 AC uptake within the MDA-MB-231 tumors by 44.8%. Conclusion: The Cbl metabolic pathway is upregulated within aggressive breast malignancies and can be biochemically targeted by a simple pulse-chase technique in vivo. The definitive mechanisms underpinning the up-regulated mitochondrial metabolism of Cbl within human breast tumors and the PC methodology remain to be elucidated. Further investigation of Cbl metabolism within benign and malignant breast tissue could potentially yield new molecular targets to detect and treat aggressive breast tumors. Citation Format: Collins DA. Cobalamin metabolism in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-05-06.
Clinical delineation of the PACS1‐related syndrome—Report on 19 patients
Background: The adductor magnus (AM) has historically been a potential source of confusion in patients with suspected proximal hamstring avulsion injuries. Purpose: To investigate the anatomic characteristics of the AM, including its osseous origin, anatomic dimensions, and relationship to the proximal hamstring tendons. Study Design: Descriptive laboratory study. Methods: Dissection of the AM origin was performed in 11 (8 cadavers) fresh-frozen hip-to-foot cadaveric hemipelvis specimens. The gross anatomy and architecture of the proximal hamstring and AM tendons were studied. After dissecting the hamstring tendons away from their origin, the dimension, shape, and orientation of the tendon footprints on the ischial tuberosity were determined. Results: The AM was identified in all cadaveric specimens. The mean tendon thickness (anterior to posterior [AP]) was 5.7 ± 2.9 mm. The mean tendon width (medial to lateral [ML]) was 7.1 ± 2.2 mm. The mean tendon length was 13.1 ± 8.7 cm. The mean footprint height (AP dimension) was 12.1 ± 2.9 mm, and mean footprint width (ML dimension) was 17.3 ± 7.1 mm. The mean distance between the AM footprint and the most medial aspect of the conjoint tendon footprint was 8.5 ± 4.2 mm. Tendon measurements demonstrated a considerable degree of both intra- and interspecimen variability. Conclusion: The AM tendon is consistently present just medial to the conjoint tendon at the ischial tuberosity, representing the lateral-most portion of the AM muscle. This study found wide variation in the dimensional characteristics of the AM tendon between specimens. Its shape and location can mimic the appearance of an intact hamstring (conjoint or semimembranosus) tendon intraoperatively or on diagnostic imaging, potentially misleading surgeons and radiologists. Therefore, detailed knowledge of the AM tendon anatomy, footprint anatomy, and its relationship to the hamstring muscle complex is paramount when planning surgical approach and technique. Clinical Relevance: The reported data may aid surgeons in more accurate recognition, diagnosis, and repair of proximal hamstring avulsion injuries.